From a voluntary vaccination policy to mandatory vaccination against COVID-19 in cancer patients: an empirical and interdisciplinary study in bioethics.
Bioethics
COVID-19
Cancer
France
Hospital
Oncology
Pandemic
Vaccine
Journal
BMC medical ethics
ISSN: 1472-6939
Titre abrégé: BMC Med Ethics
Pays: England
ID NLM: 101088680
Informations de publication
Date de publication:
28 08 2022
28 08 2022
Historique:
received:
25
01
2022
accepted:
22
08
2022
entrez:
28
8
2022
pubmed:
29
8
2022
medline:
31
8
2022
Statut:
epublish
Résumé
At the start of 2021, oncologists lacked the necessary scientific knowledge to adapt their clinical practices optimally when faced with cancer patients refusing or reluctant to be vaccinated against COVID-19, despite the marked vulnerability of these patients to severe, and even fatal forms of this new viral infectious disease. Oncologists at Foch Hospital were confronted with this phenomenon, which was observed worldwide, in both the general population and the population of cancer patients. Between April and November 2021, the Ethics and Oncology Departments of Foch Hospital decided to investigate this subject, through an empirical and interdisciplinary study in bioethics. Our scientific objective was to try to identify and resolve the principal bio-ethical issues, with a view to improving clinical practices in oncology during future major pandemics of this kind, from a highly specific bio-ethical standpoint (= quality of life/survival). We used a mainly qualitative methodological approach based on questionnaires and interviews. In April 2021, 29 cancer patients refused or were reluctant to be vaccinated (5.6%; 29/522). Seventeen of these patients said that making vaccination mandatory would have helped them to accept vaccination. In October 2021, only 10 cancer patients continued to maintain their refusal (1.9%; 10/522). One of the main reasons for the decrease in refusals was probably the introduction of the "pass sanitaire" (health pass) in July 2021, which rendered vaccination indispensable for many activities. However, even this was not sufficient to convince these 10 cancer patients. We identified a key bio-ethical issue, which we then tried to resolve: vaccination policy. We characterized a major tension between "the recommendation of anti-COVID-19 vaccination" (a new clinical practice) and "free will" (a moral value), and the duty to "protect each other" (a moral standard). Mandatory vaccination, at least in France, could resolve this tension, with positive effects on quality of life (i.e. happiness), or survival, in cancer patients initially refusing or reluctant to be vaccinated, but only if collective and individual scales are clearly distinguished.
Sections du résumé
BACKGROUND
At the start of 2021, oncologists lacked the necessary scientific knowledge to adapt their clinical practices optimally when faced with cancer patients refusing or reluctant to be vaccinated against COVID-19, despite the marked vulnerability of these patients to severe, and even fatal forms of this new viral infectious disease. Oncologists at Foch Hospital were confronted with this phenomenon, which was observed worldwide, in both the general population and the population of cancer patients.
METHODS
Between April and November 2021, the Ethics and Oncology Departments of Foch Hospital decided to investigate this subject, through an empirical and interdisciplinary study in bioethics. Our scientific objective was to try to identify and resolve the principal bio-ethical issues, with a view to improving clinical practices in oncology during future major pandemics of this kind, from a highly specific bio-ethical standpoint (= quality of life/survival). We used a mainly qualitative methodological approach based on questionnaires and interviews.
RESULTS
In April 2021, 29 cancer patients refused or were reluctant to be vaccinated (5.6%; 29/522). Seventeen of these patients said that making vaccination mandatory would have helped them to accept vaccination. In October 2021, only 10 cancer patients continued to maintain their refusal (1.9%; 10/522). One of the main reasons for the decrease in refusals was probably the introduction of the "pass sanitaire" (health pass) in July 2021, which rendered vaccination indispensable for many activities. However, even this was not sufficient to convince these 10 cancer patients.
CONCLUSION
We identified a key bio-ethical issue, which we then tried to resolve: vaccination policy. We characterized a major tension between "the recommendation of anti-COVID-19 vaccination" (a new clinical practice) and "free will" (a moral value), and the duty to "protect each other" (a moral standard). Mandatory vaccination, at least in France, could resolve this tension, with positive effects on quality of life (i.e. happiness), or survival, in cancer patients initially refusing or reluctant to be vaccinated, but only if collective and individual scales are clearly distinguished.
Identifiants
pubmed: 36031621
doi: 10.1186/s12910-022-00827-3
pii: 10.1186/s12910-022-00827-3
pmc: PMC9420182
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
88Informations de copyright
© 2022. The Author(s).
Références
Am J Bioeth. 2021 Dec;21(12):75-77
pubmed: 34806963
Eur J Cancer. 2022 Jan;160:282-284
pubmed: 34810045
Nat Commun. 2022 Jul 8;13(1):3942
pubmed: 35803909
Future Oncol. 2021 Nov;17(31):4071-4079
pubmed: 34337969
JAMA Netw Open. 2020 Oct 1;3(10):e2025594
pubmed: 33079199
Vaccines (Basel). 2021 Jul 29;9(8):
pubmed: 34451957
Front Immunol. 2021 Jun 14;12:558270
pubmed: 34194418
Nat Rev Clin Oncol. 2022 Jun;19(6):385-401
pubmed: 35277694
EClinicalMedicine. 2021 Oct;40:101113
pubmed: 34490416
J Racial Ethn Health Disparities. 2021 Oct 8;:
pubmed: 34625919
Vaccines (Basel). 2021 Jun 15;9(6):
pubmed: 34203847
JAMA Oncol. 2021 Aug 1;7(8):1242-1244
pubmed: 34110371
Lancet Reg Health Eur. 2021 Dec;11:100272
pubmed: 34841383
Support Care Cancer. 2022 Jan;30(1):289-293
pubmed: 34279721
Hum Vaccin Immunother. 2016 Sep;12(9):2464-8
pubmed: 27159558
N Engl J Med. 2021 Sep 9;385(11):e32
pubmed: 33789006
Eur J Cancer. 2021 Sep;155:54-55
pubmed: 34352570
J Natl Med Assoc. 2022 Jan;113(6):599-611
pubmed: 34158171
Transl Behav Med. 2021 Jul 29;11(7):1354-1358
pubmed: 34080616
Vaccines (Basel). 2021 Apr 21;9(5):
pubmed: 33919048
Int J Environ Res Public Health. 2021 Aug 02;18(15):
pubmed: 34360475
Isr J Health Policy Res. 2021 Mar 19;10(1):26
pubmed: 33741063
Cell Adh Migr. 2021 Dec;15(1):285-294
pubmed: 34706616
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
AJOB Neurosci. 2022 Apr-Jun;13(2):109-111
pubmed: 35324400
Eur J Cancer. 2021 Dec;159:259-274
pubmed: 34798454
JAMA Oncol. 2021 Aug 1;7(8):1133-1140
pubmed: 34047765
Glob Health Res Policy. 2021 Jul 12;6(1):23
pubmed: 34253254
R Soc Open Sci. 2020 Oct 14;7(10):201199
pubmed: 33204475
J Eval Clin Pract. 2022 Jun;28(3):493-494
pubmed: 35349216
Vaccines (Basel). 2021 Oct 12;9(10):
pubmed: 34696275
Cancers (Basel). 2021 Aug 01;13(15):
pubmed: 34359783
Bull Acad Natl Med. 2012 Mar;196(3):603-17; discussion 617-20
pubmed: 23472350
Vaccines (Basel). 2021 Jun 10;9(6):
pubmed: 34200656
Vaccines (Basel). 2021 Feb 16;9(2):
pubmed: 33669441
Ann Oncol. 2021 May;32(5):673-674
pubmed: 33529740
J Community Health. 2021 Apr;46(2):270-277
pubmed: 33389421
Int J Environ Res Public Health. 2021 May 02;18(9):
pubmed: 34063327
Med Sci (Paris). 2017 Dec;33(12):1097-1104
pubmed: 29261498
Nat Rev Clin Oncol. 2019 Apr;16(4):205-206
pubmed: 30552396
BMJ. 2020 Apr 2;369:m1291
pubmed: 32241762
ESMO Open. 2021 Feb;6(1):100027
pubmed: 33399089
BMJ. 2021 Aug 4;374:n1903
pubmed: 34348941
Lancet Respir Med. 2022 Mar;10(3):221-222
pubmed: 35151375
JAMA Oncol. 2021 Aug 1;7(8):1123-1125
pubmed: 34047766
NPJ Vaccines. 2021 May 14;6(1):73
pubmed: 33990614
Nat Commun. 2022 Jul 1;13(1):3801
pubmed: 35778396
JAMA Oncol. 2021 Aug 1;7(8):1113-1114
pubmed: 33983372
Hum Vaccin Immunother. 2022 Jun 8;:2082793
pubmed: 35674781
Expert Rev Vaccines. 2021 Oct;20(10):1201-1209
pubmed: 34488546
Lancet Infect Dis. 2022 Feb;22(2):152-153
pubmed: 34756187
Front Public Health. 2021 Jul 26;9:614499
pubmed: 34381748
Expert Rev Vaccines. 2015 Jan;14(1):99-117
pubmed: 25373435
N Engl J Med. 2021 Oct 28;385(18):1718-1720
pubmed: 34496200
PLoS One. 2021 Apr 28;16(4):e0250797
pubmed: 33909687
Ethique Sante. 2021 Jun;18(2):96-101
pubmed: 33897856
JAMA Netw Open. 2021 Sep 1;4(9):e2126882
pubmed: 34559232
Lancet Public Health. 2021 Apr;6(4):e210-e221
pubmed: 33556325
Lancet Infect Dis. 2021 May;21(5):e110
pubmed: 32941786
Eur J Cancer. 2021 Aug;153:260-264
pubmed: 34183225